Tesamorelin late phase trial… Although there is an increasing need for effective treatments for NAFLD and NASH, until very recently, no specific on-label treatment had been approved or recommended (60). Furthermore, treating patients with both type 2 diabetes and NAFLD or NASH is complex and challenging because of the various comorbidities that frequently exist in these patients (61), and data from clinical trials of antidiabetic treatment typically lack high-quality and clinically relevant endpoints related to liver histology. Of note, saroglitazar, a dual PPARα/γ agonist, was approved in India in March 2020 for the treatment of NASH. However, at the time of writing this review, there are currently no drugs approved by the FDA or European Medicine Agency for this disease. Nevertheless, several drugs being developed for the treatment of NASH are currently in advanced phase 3 clinical trials (e.g., obeticholic acid, cenicriviroc, aramchol, resmetirom, dapagliflozin, and semaglutide). Moreover, others in the pipeline (e.g., elapectin, MSDC-0602K, lanifibranor, efruxifermin, and tesamorelin) are expected to commence late-phase trials in the near future (62).
https://www.frontiersin.org/articles/10.3389/fendo.2021.768850/full